Company intelligence / Profile preview

Quercus Molecular Design

Avon or Farmington (sources mention both), Connecticut, United Statesquercusmoleculardesign.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Quercus Molecular Design is developing a platform for rationally designed small molecule inhibitors that simultaneously target multiple essential proteins involved in infectious diseases and cancer. The company is currently focused on preclinical research, leveraging expertise in molecular virology, drug resistance, cancer therapeutics, and medicinal chemistry. No clinical results have been published to date.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculesMulti-targeting inhibitors
Industry: Biotech

Beyond the preview

Go deeper on Quercus Molecular Design.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quercus Molecular Design.

Explore the full profile